Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A

Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins

(2018) Thomas Pirzer et al.   ACS Chemical Biology

High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers

(2018) Rachana Ohri et al.   BIOCONJUGATE CHEMISTRY

Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity

(2018) Junxia Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity

(2018) Ronit Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Peptide-Directed Photo-Cross-Linking for Site-Specific Conjugation of IgG

(2018) Jisoo Park et al.   BIOCONJUGATE CHEMISTRY

Moxetumomab Pasudotox: First Global Approval

(2018) Sohita Dhillon   DRUGS

Nucleic Acid Detection by a Target-Assisted Proximity Proteolysis Reaction

(2018) Hyeon Ji Park et al.   ACS Sensors

Immunotoxins in cancer therapy: Review and update

(2017) Bahman Akbari et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance

(2017) Migyeong Jo et al.   mAbs

Immunotoxin: A new tool for cancer therapy

(2017) Hossein Allahyari et al.   TUMOR BIOLOGY

Use of a next generation maleimide in combination with THIOMAB™ antibody technology delivers a highly stable, potent and near homogeneous THIOMAB™ antibody-drug conjugate (TDC)

(2017) João P. M. Nunes et al.   RSC Advances

Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping

(2017) Xiaofeng Dai et al.   Journal of Cancer

From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance

(2017) David W. Scott   Frontiers in Immunology

One-Step Conjugation Method for Site-Specific Antibody–Drug Conjugates through Reactive Cysteine-Engineered Antibodies

(2016) Daisuke Shinmi et al.   BIOCONJUGATE CHEMISTRY

Dual Unnatural Amino Acid Incorporation and Click-Chemistry Labeling to Enable Single-Molecule FRET Studies of p97 Folding

(2016) Taehyung C. Lee et al.   CHEMBIOCHEM

Probing unnatural amino acid integration into enhanced green fluorescent protein by genetic code expansion with a high-throughput screening platform

(2016) Georg Wandrey et al.   Journal of Biological Engineering

A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma

(2016) Jinxu Fang et al.   Molecular Therapy-Oncolytics

Incorporation of Unnatural Amino Acids in Response to the AGG Codon

(2015) Byeong Sung Lee et al.   ACS Chemical Biology

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics

(2015) Eunhee G. Kim et al.   Biomolecules & Therapeutics

Current methods for the synthesis of homogeneous antibody–drug conjugates

(2015) Alicja M. Sochaj et al.   BIOTECHNOLOGY ADVANCES

Advances in Anticancer Immunotoxin Therapy

(2015) C. Alewine et al.   ONCOLOGIST

Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics

(2015) Steven A. Jacobs et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Site-Specific Protein Immobilization Using Unnatural Amino Acids

(2014) Benjamin K. Raliski et al.   BIOCONJUGATE CHEMISTRY

Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy

(2014) T.-H. Shin et al.   MOLECULAR CANCER THERAPEUTICS

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

(2014) R. Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Unnatural amino acid incorporation in E. coli: current and future applications in the design of therapeutic proteins

(2014) Kim Wals et al.   Frontiers in Chemistry

Albumin as a versatile platform for drug half-life extension

(2013) Darrell Sleep et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Quantification of thiols and disulfides

(2013) Jakob R. Winther et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

Immunotoxins: The Role of the Toxin

(2013) Antonella Antignani et al.   Toxins

Synthesis of Bispecific Antibodies using Genetically Encoded Unnatural Amino Acids

(2012) Chan Hyuk Kim et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

(2012) W. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

(2012) H. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

(2012) J. Y. Axup et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Optimized clinical performance of growth hormone with an expanded genetic code

(2011) H. Cho et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Analysis and Optimization of Copper-Catalyzed Azide–Alkyne Cycloaddition for Bioconjugation

(2009) Vu Hong et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

(2009) D. Dornan et al.   BLOOD

Expanding the Genetic Code for Biological Studies

(2009) Qian Wang et al.   CHEMISTRY & BIOLOGY

An Enhanced System for Unnatural Amino Acid Mutagenesis in E. coli

(2009) Travis S. Young et al.   JOURNAL OF MOLECULAR BIOLOGY

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

(2008) J. E. Weldon et al.   BLOOD

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY